Also categorized in Clinical Research:
A Phase I Study of the Hu3F8 Antibody plus GM-CSF in Patients with Relapsed/Refractory Neuroblastoma
x hide permanently

GPC2 May Be an Immunotherapeutic Target in High-Risk Neuroblastoma.

ncbi.nlm.nih.gov

GPC2 May Be an Immunotherapeutic Target in High-Risk Neuroblastoma.

Cancer Discov. 2017 Sep 22;:

Authors:

Abstract A GPC2-targeting antibody-drug conjugate promotes tumor regression in a high-risk neuroblastoma PDX.

PMID: 28939655 [PubMed - as supplied by publisher]

Mentions: Antibody